Teva Pharmaceutical Industries Limited (TEVA) : Traders are bullish on Teva Pharmaceutical Industries Limited (TEVA) as it has outperformed the S&P 500 by a wide margin of 3.94% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.9%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.33% in the last 1 week, and is up 6.52% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $55.20 on Friday but the bulls could not build on the opening and the stock topped out at $55.45 for the day. The stock traded down to $54.04 during the day, due to lack of any buying support eventually closed down at $54.21 with a loss of -2.24% for the day. The stock had closed at $55.45 on the previous day. The total traded volume was 6,582,278 shares.
The stock has recorded a 20-day Moving Average of 0.61% and the 50-Day Moving Average is 2.95%. Teva Pharmaceutical Industries Limited is up 8.56% in the last 3-month period. Year-to-Date the stock performance stands at -16.36%.
Teva Pharmaceutical Industries Limited (TEVA) : Currently there are 17 street experts covering Teva Pharmaceutical Industries Limited (TEVA) stock. The most bullish and bearish price target for the stock is $100 and $55 respectively for the short term. The average price target of all the analysts comes to $73.11. The estimated standard deviation from the target is $9.81.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.